title: Rapamycin: one drug, many effects.
abstract: The mammalian target of rapamycin (mTOR) signaling pathway is a master regulator of cell growth and metabolism. Deregulation of the mTOR pathway has been implicated in a number of human diseases such as cancer, diabetes, obesity, neurological diseases, and genetic disorders. Rapamycin, a specific inhibitor of mTOR, has been shown to be useful in the treatment of certain diseases. Here we discuss its mechanism of action and highlight recent findings regarding the effects and limitations of rapamycin monotherapy and the potential utility of combination therapy with rapamycin.
authors: Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA.
authors: Jing
authors: J
authors: Li
authors: Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA.
authors: Sang Gyun
authors: SG
authors: Kim
authors: Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA. Electronic address: john_blenis@hms.harvard.edu.
authors: John
authors: J
authors: Blenis
mesh_terms: D000375:Aging / Q000187:drug effects; D004359:Drug Therapy, Combination; D006801:Humans; D008136:Longevity / Q000187:drug effects; D008171:Lung Diseases / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D008659:Metabolic Diseases / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D009422:Nervous System Diseases / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D015398:Signal Transduction / Q000187:drug effects*; D020123:Sirolimus / Q000494:pharmacology* / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus